Graduated with honors in Chemistry and then received PhD in biochemistry and molecular biology. Have over 20 years of experience in tutoring highschool, graduate and medical school students in the area of sciences. Work with students to give them methods and examples to follow when mastering the science subjects. Years of experience have taught me how to articulate the sciences for everyone's understanding in order to allow the student to enjoy the sciences and master the understanding.
Have over 20 years of experience in tutoring and mentoring highschool, graduate and medical school students in the area of sciences. Have tutored over 100 students over the years and am responsible for medical school applicant acceptances, graduate student acceptances and highschool and advanced degree diplomas. Have also taught courses in biochemistry, molecular biology at Universities with over 20 students in respective courses.
From 2005-2010, I served as Director of the Cancer Research Institute of M. D. Anderson Cancer Center Orlando. I was recruited from M. D. Anderson Cancer Center in Houston, by way of Harvard. I completed my post-doctoral fellowship in the Department of Cancer Biology at The University of Texas M. D. Anderson Cancer Center in Houston, Texas under the renowned Dr. Isaiah Fidler. For several years, I conducted research in the laboratory of Dr. Judah Folkman at the Boston Children’s Hospital and Harvard Medical School. I have extensive experience in cell-based assays (using human and normal cell lines), orthotopic animal models, live animal imaging, and in vivo analysis.
B. Positions and Honors Positions and Employment
1995-1999 Research Assistant, Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX
1997-1998 Instructor of Chemistry and Biochemistry, Kaplan Center, Lubbock, TX
1998-1999 Instructor of Chemistry and Society II, Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX
1999-2001 Post-Doctoral Fellow, Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX
2002-2003 Instructor of Surgery, Department of Surgery, Harvard Medical School, Children’s Hospital, Boston, MA
2003-2005 Assistant Professor, Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX
2005-2010 Director, Assistant Professor, Cancer Research Institute of M. D. Anderson Cancer Center Orlando
2005–2015 Adjunct Assistant Professor, Burnett School of Biomedical Sciences, UCF
2007-present Adjunct Professor, UCF College of Medicine, Orlando, FL
2010-present Co-Founder, Chief Scientific Research Officer, BioCurity Holdings, Inc.
2011-2013 Adjunct Assistant Professor, Rollins College, Winter Park, Florida
Honors and Awards
1994 Member of Phi Lambda Upsilon, National Honorary Chemical Society
1994 Rollins College Department of Chemistry Outstanding Undergraduate Student Award 1994 Graduated cum laude Chemistry, Department of Chemistry, Rollins College
1996 Texas Tech University Department of Chemistry Outstanding Graduate Teaching Assistant Award
1997 Texas Tech University Graduate School Summer Dissertation Award
1997 Outstanding graduate paper and presentation at 24th Annual Student Research Conference at Eastern New Mexico University (Sponsored by American Chemical Society)
1998 Achievement Award for College Scientists (ARCS) Recipient Scholar (Lubbock Chapter, ARCS Foundation, Inc.)
2000-2001 AACR-AFLAC Scholar in Cancer Research
2002 4th International Symposium on Anti-Angiogenic Agents Travel Fellowship Award
2004 1st European Conference on Tumor Angiogenesis and Antiangiogenic Therapy Presentation Award
2004-2005 American Association for Cancer Research, Associate Member Council Chairperson
2005 American Association for Cancer Research: In recognition of dedicated service on behalf of Associate Members and other scientists early in their careers
2010 Medical Marker Award from Mayor Dyer for Advancing the Life Sciences in Central Florida
Mentorship of Graduate Students at The University of Central Florida:
Master level students and PhD students
C. Selected Peer-reviewed Publications
1. Baker, C.H., Belduz, A.O., Lee, E.J., Leu, S-F., and Harman, J.G. Protein/Ligand Interactions Important for the Activation of a Bacterial Transcription Factor: Site-Directed Mutagenesis of the Cyclic AMP Receptor Protein. SAAS Bulletin 2:27-32, 1998.
2. Leu, S-F., Baker, C.H., and Harman, J.G. Position 127 Amino Acid Substitutions Affect the Formation of CRP:cAMP:lacP Complexes but NOT CRP:cAMP:RNA Polymerase Complexes at lacP. Biochemistry, 38:6222-6230, 1999.
3. Baker, C.H., Tomlinson, S.R., Garcia, A.E., and Harman, J.G. Amino Acid Substitution at Position 99 Affects the Rate of CRP Subunit Exchange. Biochemistry, 40:12(concealed information), 2001.
4. Baker CH, Solorzano CC, Fidler IJ. Angiogenesis and Cancer Metastasis: Antiangiogenic Therapy of Human Pancreatic Adenocarcinoma. Int J Clin Oncol. 2001;6:59-65.
5. Baker CH, Solorzano CC, Fidler IJ. Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer. Cancer Res. 2002;62:1996-2003.
6. Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ. Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Human Carcinomas. Am J Pathol. 2002;161(3):929-38.
7. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and Qualitative In Vivo Angiogenesis Assay. Int J Oncol. 2002;21:5-10.
8. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O’Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of Biological Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin. J Clin Oncol. 2002;18:3804-14.
9. Kedar D, Baker CH, Killion JJ, Dinney CPN, Fidler IJ. Blockade of the Epidermal Growth Factor Receptor Signaling Inhibits Angiogenesis Leading to Regression of Human Renal Cell Carcinoma Growing Orthotopically in Nude Mice. Clin Cancer Res. 2002;8:3592-600.
10. Weber KL, Doucet M, Price JE, Baker CH, Kim SJ, Fidler IJ. Blockade of Epidermal Growth Factor Receptor Signaling Leads to Inhibition of Renal Cell Carcinoma in the Bone of Nude Mice. Cancer Res. 2003;63:2940-7.
11. Heymach JV, Force P, Beaudry P, Wang AC, Baker CH, Ryan A, Soker S, Folkman J. Differential Effects of VEGFR-2 Inhibition on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker. Clin Cancer Res. 2005;9:3514-22.
12. Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, Gallick GE. Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis. Cancer Res. 2005;6:7214-22.
13. Szentirmai O, Baker CH, Takahastu M, Mulligan R, Carter B. Longitudinal Monitoring of Intracranial Glioblastoma Xenograft Growth Using Bioluminescence. Neurosurgery. 2006;2:365-72.
14. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model. Am J Pathol. 2006;168:962-72.
15. Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HS, Abbruzzese JL, McConkey DJ. TGF-alpha expression drives constitutive EGFR pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res. 2006;66:3802-12.
16. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic Acid, A Nonsteroidal Anti-Inflammatory Drug, Inhibits Pancreatic Cell/Tumor Growth and Angiogenesis Through Downregulation of Sp proteins. J Natl Cancer Inst. 2006;12:855-68.
17. Baker CH, Trevino JG, Summy JM, Zhang F, Caron A, Nesbit M, Gallick GE, Fidler IJ. Inhibition of PDGFR Phosphorylation, Src and Akt Activities by GN963 Leads to Therapy of Human Pancreatic Cancer Growing Orthotopically in Nude Mice. Int J Clin Oncology. 2006;29:125-38.
18. Baker CH, Pino MS, Fidler IJ. Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells in Human Renal Cell Carcinoma is a Primary Target for Therapy by Tyrosine Kinase Inhibitors. Neoplasia. 2006;8:470-6.
19. Wu W, O’Reilly MS, Langley R, Tsan RT, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of EGF/TGF-Alpha by Human Lung Cancer Cells Determines Response to EGFR Kinase Inhibitors. Molecular Cancer Therap. 2007, 10:2652-63.
20. Abdelrahim, M., Safe, S., Baker, C.H., and Abudayyeh, A. RNAi and Cancer: Implications and Applications. Journal of RNAi and Gene Silencing. 2(1), 136-145, 2006.
21. Abdelrahim, M., Baker, C.H., Abbruzzese, J. L., Sheikh-Hamad, D., Liu, S., Dae Cho, S., Yoon, Y., and Safe, S. Regulation of Vasculature endothelial growth factor receptor-1 (VEGFR-1) Expression by Specificity Protein 1,3, and 4 in Pancreatic Cancer Cells. Cancer Research, 67:3286-3295, 2007.
22. Baker, C.H., and Fidler, I.J. The Tumor Microenvironment and Angiogenesis. In: Anti-Angiogenic Cancer Therapy, Chapter, 5. pp 131-149. CRC Press and Taylor and Francis Company. 2007.
23. Szentirmai O*, Baker CH*, Bullain SS, Lin NL, Takahastu M, Folkman J, Mulligan R, Carter B. Successful inhibition of intracranial human glioblastoma xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble VEGF-receptor-2. J. Neurosurgery. 2008:5:979-988.
* authors contributed equally.
24. Krajewska M, Winter JN, Lichtenstein A, Zhai D, Cuddy M, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Huang X, Duffy MJ, Schimmer AD, Mercola D, Krajewski S and Reed JC. Bcl-B expression in human non-epithelial and epithelial malignancies. Cancer Res., 2008:10:3011-21.
25. Colon J, Herrera L, Smith J, Patil S, Komanski C, Kupelian P, Seal S, Jenkins DW, Baker CH. Protection of Radiation-Induced Pneumonitis Using Cerium Oxide Nanoparticles. Nanomedicine, 2009:2:225-231.
26. Konduri SD, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic Acid Enhances Pancreatic Cancer Cell and Tumor Response to Radiation Therapy by Inhibiting Survivin Protein Expression. Mol. Cancer Ther. 2009; 8(3) 533-542.
27. Papineni S, Chintharlapalli S, Abdelrahim M, Lee S, Burghardt R, Abudayyeh S, Baker CH, Herrera L, and Safe S. Tolfenamic Acid Inhibits Esophageal cancer Through Repression of Specificity Proteins and c-Met. Carcinogenesis, 2009:7:1193-1201.
28. Basha R, Baker CH, Abdelrahim M. Biomarkers Clinical Relevance in Cancer: Emphasis on Breast Cancer and Prostate Cancer. Current Trends in Biotechnology and Pharmacy, 3:1-7, 2009.
29. Donigan M, Loh B, Norcross LS, Li S, Williamson R, DeJesus S, Ferrara A, Gallagher JT, Baker CH. A Metastatic Colon Cancer Model Using Non-Operative Trans-anal Rectal Injection. Surgical Endoscopy, 2010:3:642-647.
30. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH. Novel Murine Model for Colon Cancer: Non-operative Trans-anal Rectal Injection. Journal of Surgical Res., 2009:2:299-303.
31. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis, JL. Tissue factor- bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008: 9:1517-1524.
32. Konduri SD, Ticku J, Bobustuc GC, Sutphin RM, Colon J, Bhakat KK, Kalkunte SK, Baker CH. Blockade of MGMT Expression by O6 Benzyl Guanine Leads to Inhibition of Pancreatic Cancer Growth and Induction of Apoptosis. Clin. Cancer Res., 2009:15:6087-6095.
33. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Avgeropoulos, NG, Konduri SD. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro-Oncology, 2010:12:917-927.
34. Abdelrahim M, Konduri S, Basha R, Philip P, Baker CH. Angiogenesis: An Update and Potential Drug Approaches. Int. J. Oncol. 2010:1:5-18.
35. Colon J, Basha R, Madero R, Konduri S, Baker CH, Herrera L, Safe S, Sheikh-Hamad D, Alvarado B, Abdelrahim M. Tolfenamic Acid Inhibits Lung Cancer and Tumor Growth by Repressing Specificity Proteins and c-Met. Investigational New Drugs, 2011:29:41-51.
36. Kuchma M, Komanski CB, Colon C, Teblum A, Masunov AE, Alvarado B, Babu S, Seal S, Summy J, Baker CH. Phosphate ester hydrolysis of biologically relevant molecules by cerium oxide nanoparticles. Nanomedicine, 2010:6:738-744.
37. Colon J, Hsieh N, Ferguson A, Kupelian P, Seal S, Jenkins DW, Baker CH. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine, 2010:6:698-705.
38. Bogdanovoic J, Colon J, Baker CH, Huo Q. A Label-Free Nanoparticle Aggregation Assay for Protein Complex/Aggregate Detection and Study. Analytical BioChemistry, 2010:1:96-102.
39. Suresh Babu, S Cho J-H, Dowding JM, Heckert E, Komanski C, Das S, Colon J, Baker CH, Bass M, Self WT, Seal S. Multicolored redox active upconverter cerium oxide nanoparticle for bio-imaging and therapeutics. Royal Society of Chemistry, Chem. Comm., 2010:46:6915-6917.
40. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim M. Therapeutic applications of NSAIDs in cancer: special emphasis on tolfenamic acid. Front Biosci (Schol Ed). 2011:3:797- 805.
41. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Sumant Kaja AS, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Investigational New Drugs, 2011 [Epub ahead of print].
42. Smith JS, Colon J, Madero-Visbal R, Isley B, Konduri, SD, Baker CH. Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells. Anticancer Agents Med Chem. 2010:8:6640-6650.
43. Basha R, Ingersoll SB, Umesh ST, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim
M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecologic Oncology, 2011:122:163–170.
44. Madero-Visbal R, Colon J, Limaye A, Smith J, Hernandez IC, Lee C, Herrera L, Arlen PA, Baker CH. Bioluminescence Imaging Correlates with Tumor Progression in an Orthotopic Mouse Model of Lung Cancer. Surgical Oncology. 2012:21:23-29.
45. Madero-Visbal RA, Alvarado BE, Colon JF, Baker CH, Wason MS, Isley B, Seal S, Lee CM, Das S, Mañon
R. Nanomedicine. Harnessing Nanoparticles to Improve Toxicity after Head and Neck Radiation. 2012:7:1223- 1231.
46. Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD. MGMT Inhibition Restores ERα Functional Sensitivity to Antiestrogen Therapy. Mol. Medicine. 2012;7:913-929.
47. Melissa S. Wason, Jimmie Colon, Soumen Das, Sudipta Seal, James Turkson, Jihe Zhao, and Cheryl H. Baker. Sensitization of Pancreatic Cancer Cells to Radiation by Cerium Oxide Nanoparticle-Induced ROS Production. Nanomedicine: Nanotechnology, Biology and Medicine, 2013;4:558-569.
48. Baker, CH. Harnessing cerium oxide nanoparticles to protect normal tissue from radiation damage. Translational Cancer Research. 2013: Vol 2, No 4. (concealed information)
49. Baker, CH. Radiation Protection Using Nanoparticles. 2014. JSM Nanotechnol Nanomed 2(1):1019.
D. Research Support Completed Research Support
Grant #2RO1CA(concealed information); National Institutes of Health/National Cancer Institute, Role: Co-Principal Investigator, Discovery of Novel Antitumor Agents Effective Against Pancreatic Cancer, (Principal Investigator, Wright) July 2010 – April 2013.
Grant #09BN-01: Bankhead-Coley Cancer Research Program New Investigator Research Grant, Florida Department of Health, Role: Principal Investigator, Nanoceria: A Novel Nanoparticle Adjuvant Therapy to Increase the Efficacy of Radiotherapy for Lung Cancer Patients. July 1, 2009- June 30, 2012.
Grant #09BN-10-23090: Bankhead-Coley Cancer Research Program, New Investigator Research Grant, Florida Department of Health, Role: Mentor, Discovery of Novel Anti-inflammatory Compounds for Use as Chemopreventatives of Pancreatic Cancer, (Principal Investigator; Guzman), July 1, 2009- June 30, 2012.
Grant #08BN-06-17197: Bankhead-Coley Cancer Research Program New Investigator Research Grant, Florida Department of Health, Role: Co-Investigator, SHP-2 and Src in Pancreatic Cancer Cell Biology, Tumorigenesis, and Metastasis, (Principal Investigator: Summy) July 1, 2008- June 30, 2011.
Grant #09BB-01-23061: Bankhead-Coley Cancer Research Program Bridge Research Grant, Florida Department of Health, Role: Co-Investigator, The Role of Extracellular Cytokeratin 8 in Prostate Cancer, (Principal Investigator: Arlen), July 1, 2009-June 30, 2010.
Grant #08KN-13: James and Esther King Biomedical Research Program, Florida Department of Health, Role: Collaborator, Protease Inhibition of Invasion in Head and Neck Cancer, (Principal Investigator: Shellenberger), July 1/2008 – June 30/2011.
Grant #09BN-10-23090: Bankhead-Coley Cancer Research Program, New Investigator Research Grant, Florida Department of Health, Role: Collaborator, Novel insights in Tamoxifen Regulation of MGMT Expression in Human Breast Cancers and Its Therapeutic Relevance, (Principal Investigator: Konduri), July 1, 2009- June 30, 2012.
Grant #09BB-01: Bankhead-Coley Cancer Research Program Bridge Research Grant, Florida Department of Health, Role: Co-Investigator, Development of a Homogeneous One-Step Immunoassay for Cancer Biomarker Detection, (Principal Investigator: Huo), July 1, 2009- June 30, 2010.
Grant #2006: Fraternal Order of Eagles/Art Ehrmann Cancer Fund, Role: Principal Investigator, Antivascular Therapy of Human Cancers, September 1, 2006 – August 31, 2009.
Grant #07BN-01: Bankhead-Coley Cancer Research Program New Investigator Research Grant, Florida Department of Health, Role: Co-Investigator, Inhibition of Pancreatic Cancer Growth and Metastasis by NSAIDs and Derivatives, (Principal Investigator: Abdelrahim), July 1, 2007 – June 30, 2009.
Grant #02-18C-NNJ: Dana-Farber/Harvard Cancer Center New Nodal Interactions Support, Role: Principal Investigator, Anti-Angiogenic Adeno-Associated Virus Gene Therapy for Glioma, July 1, 2002 – July 1, 2004.
Grant #74-6001118: University of Texas M. D. Anderson Cancer Center, Gillson Longenbaugh Foundation, Role: Principal Investigator, Therapy of Human Pancreatic Cancer Metastasis, October 1, 2004 – May 1, 2006.
Grant # 0(concealed information): Merck - Treatment of Human Pancreatic Cancer and Human Colorectal Cancer in Orthotopic Murine Models by the Insulin-liked Growth Factor Receptor 1 (IGF-1R) Inhibitor (MK-0646) in combination therapies, Role: Principal investigator, July 1, 2008- September 30, 2009.
Cheryl is a warm hearted, kind and deeply caring compassionate person. She would not let another down or fail, not her friends her family and most importantly her 2 sons Tyler and Cole.
Cheryl is also a brilliant mind. A PHD, I had the honor of being taught by her knowledge about her discovery, her taking many years to research and develop a cancer drug that will benefit chemo patients.
Most importantly is that Cheryl carefully thoroughly sees through and understands all subject matter pertaining to her knowledge. If I had a math or science tutor I would choose Cheryl. A deep intuitive understanding of people, children and all learning abilities.
other sciences lessons close by? Here's a selection of teacher ads that you can check out.
|at her home||at your home||By webcam|